IGF2BP2 and breast cancer: Overexpression of IGF2BP2 has been found to confer shorter survival and poor prognosis in multiple cancers (39), including breast cancer (40), hepatocellular carcinoma (41), and pancreatic ductal adenocarcinoma (42, 43).